Sankt Johann In Tirol

Researchers are conducting the Austrian Hypertrophic Cardiomyopathy (HCM) Registry, a prospective multicenter study enrolling patients from various outpatient clinics across Austria, including both academic and non-academic centers. The study focuses on patients with hypertrophic cardiomyopathy, aiming to collect detailed clinical and genetic data to improve understanding and care standards for this condition. The registry supports innovative research and facilitates both cross-sectional and long-term epidemiological analyses to identify evidence gaps in HCM management. Participants will undergo a structured examination that includes evaluation of HCM symptoms, medical and family history, medication use, and detection of HCM-specific warning signs. Clinical assessments will involve electrocardiograms, echocardiography, laboratory tests, and genetic testing. Data collected will be entered into an electronic case report form to enable multicenter data analysis, overseen by a steering committee with representatives from each site. During the study, researchers will monitor all-cause mortality and cardiovascular events over an average follow-up period of 20 years. The study involves ongoing data collection and standardized clinical assessments to harmonize care for HCM patients in Austria. Data access for research requires approval by the steering committee, ensuring regulated use of the information collected throughout the study duration.

Researchers are evaluating the safety and effectiveness of hip implants produced by Falcon Medical, specifically focusing on the PROMIS Stem used in primary total hip arthroplasty (THA). This study includes patients with various hip conditions such as hip arthropathy, osteoarthritis, Perthes disease, osteonecrosis, and femoral neck fractures who are receiving these implants. The goal is to monitor how well these implants perform and ensure their continued improvement. The study involves the use of the PROMIS Stem device during primary total hip arthroplasty procedures. All patients in the study will receive this specific implant as part of their surgery. The implants are part of ongoing development by Falcon Medical and are being monitored closely to assess their clinical performance. Participants will be followed to track outcomes including any complications during or soon after surgery, the need for revision surgeries, and patient-reported outcomes through the WOMAC questionnaire. Data will be collected prospectively in a standardized manner, and one of the main long-term measures is stem migration over a 20-year period. The study includes a total of 250 hip arthroplasty cases performed at a single hospital, ensuring comprehensive monitoring of implant safety and efficacy.

Researchers are evaluating the safety and effectiveness of the LatGYNious, a specially designed pelvic floor mesh implant, for treating pelvic organ prolapse in women. This condition involves the descent of pelvic organs, and the study aims to generate clinical data to support the use of this device in surgical treatment. The trial focuses on female participants with symptomatic prolapse of grade 2 or higher in one of the pelvic compartments, with or without the uterus. The LatGYNious device combines two types of polypropylene mesh materials to provide both elasticity and strong lateral fixation. The mesh is implanted using a laparoscopic lateral suspension technique, either preserving the uterus or following a hysterectomy. In cases where the uterus is preserved, part of the mesh is removed to accommodate. The study assesses the performance and safety of this device during and after surgery. Participants will be followed up for 6 and 12 months after surgery to measure the success of the treatment. Researchers will monitor pelvic organ prolapse symptoms and any adverse effects related to the mesh implant. The study requires participants to attend follow-up examinations and provide informed consent to participate and share their health information for research purposes.